Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.


The Cyfra 21.1 assay is a newly developed test which measures in serum a fragment of cytokeratin 19. We evaluated this marker in 212 patients with non-small-cell lung cancer (NSCLC), predominantly stage 3a-b and 4, and compared it with three other markers: carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC) and tissue polypeptide antigen… (More)
DOI: 10.1038/bjc.1994.95


9 Figures and Tables